Obesity
From the AGA Journals
Experts offer guidance on GLP-1 receptor agonists prior to endoscopy
A Clinical Practice Update from the AGA addresses concerns over delayed gastric emptying and aspiration during sedation.
From the Journals
GLP-1 agonists linked to higher risk for rare but serious GI complications
Investigators say their findings are not about scaring people off the weight-loss drugs, but instead about increasing awareness that these...
Commentary
Obesity in GI care
While AGA's advocacy efforts related to access to colorectal cancer screening are frequently highlighted, this is but one aspect of a much larger...
News from the FDA/CDC
FDA gives semaglutide two drug safety–related label changes
The second addition concerns a new adverse reaction that was identified during the postmarketing experience: gastrointestinal ileus, an intestinal...
Supplements
Gastroenterology Data Trends 2023
News from the AGA
Landmark obesity legislation reintroduced in Congress
The passage of TROA could lead to improved obesity care because many private insurance companies model their covered health benefits to reflect...
From the Journals
Study documents obesity-related defecation disorders
“These results support the notion that rectal evacuation disorder/incomplete evacuation may be an important underlying mechanism for fecal...
From the Journals
Poor weight loss after bariatric surgery? Liraglutide may help
“The practice of combination therapy will grow as [metabolic and bariatric surgery] and [antiobesity medications] work in synergy.”
From the Journals
One type of bariatric surgery betters IBD outcomes
Previous studies have shown that bariatric surgery is safe for people with IBD, but there have been few long-term data on whether the weight loss...
Conference Coverage
Triple-agonist retatrutide hits new weight loss highs
“I have never seen weight loss at this level” after nearly 1 year of treatment.